ILC is the second most common type of breast cancer after invasive ductal carcinoma. More than 180,000 women in the U.S. find out they have invasive breast cancer each year, according to the American Cancer Society. F-18 FES is a PET radiotracer approved by the U.S. Food and Drug Administration in May 2020 for detecting estrogen receptor (ER)-positive lesions as an adjunct to biopsy in women with recurrent or metastatic breast cancer.
Performance of the tracer in women with ILC is understudied, according to a team at the University of Utah.
Presenter Dr. Matthew Covington, an assistant professor of radiology at the university's Huntsman Cancer Institute, will discuss details of the radiotracer's performance in a pilot study of 17 women with histologically proven ILC. The study authors compared F-18 FES detection rates to a positive detection rate for FDG of 60% (based on a literature review).
F-18 FES showed uptake in 22 of 25 lesions (88%) and uptake in 14 of 17 subjects (82.4%). In addition, the researchers found FES PET/CT and FDG PET/CT were superior in evaluating extent of disease and nodal metastatic disease compared to ultrasound and breast MRI.
The study is ongoing, Covington noted, adding that larger multicenter studies are needed to clarify the role of FES PET/CT for the evaluation and management of ER-positive breast malignancy.
Attend the session to learn more.